SCHEMBL4873941

SCHEMBL4873941

Cc1nc(C(=O)Nc2ccc(NCCO[Si](C)(C)C(C)(C)C)cc2)c(C(=O)Nc2ccc(Cl)cn2)s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 2/20 0.40
RAB9A P51151 9/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
F10 P00742 2/20 0.38
NPC1 O15118 5/20 0.38
NFKB1 P19838 2/20 0.38
NFKB2 Q00653 2/20 0.38
RELA Q04206 2/20 0.38
LMNA P02545 2/20 0.38
ALDH1A1 P00352 1/20 0.38
CASP3 P42574 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
SENP6 Q9GZR1 1/20 0.38
TRPV4 Q9HBA0 1/20 0.37
TP53 P04637 1/20 0.37
TSHR P16473 1/20 0.37
DGAT1 O75907 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14066579 1.00 GRM5 (0.40) GRM5RAB9ASMN1; SMN2L3MBTL1F10
SCHEMBL4710501 0.86 RAB9A (0.42) RAB9ASMN1; SMN2L3MBTL1NPC1NFKB1
SCHEMBL4885688 0.85 RAB9A (0.35) GRM5RAB9ASMN1; SMN2L3MBTL1F10
SCHEMBL14066578 0.83 F10 (0.43) RAB9ASMN1; SMN2F10NPC1NFKB1
SCHEMBL4882648 0.83 F10 (0.43) RAB9ASMN1; SMN2F10NPC1NFKB1
SCHEMBL4875148 0.82 RAB9A (0.41) RAB9ASMN1; SMN2L3MBTL1F10NPC1
SCHEMBL14066580 0.81 MAPT (0.53) SMN1; SMN2L3MBTL1ALDH1A1NPSR1KDM4E
SCHEMBL4881605 0.78 KMT2A (0.43) GRM5RAB9ASMN1; SMN2L3MBTL1NPC1
SCHEMBL4877155 0.76 F10 (0.40) RAB9ASMN1; SMN2F10NPC1NFKB1
SCHEMBL4881623 0.75 SMN1; SMN2 (0.38) GRM5RAB9ASMN1; SMN2L3MBTL1F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080214533-A1 Cyclic Iminocarbamates And Their Use BAYER HEALTHCARE AG (DE) 2008-09-04 US disclosed
US-20080214533-A1 Cyclic Iminocarbamates And Their Use BAYER HEALTHCARE AG (DE) 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214533-A1 Cyclic Iminocarbamates And Their Use F2, UQCRB, F12 GRM5 4466/4885RAB9A 2655/4885SMN1; SMN2 2534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.